Figure 13.

A 60-year-old breast cancer patient (HER2 +ve) was administered with ¹⁷⁷Lu-DOTA-trastuzumab therapy. A. WBS at day 1 and day 7 post administration of ¹⁷⁷Lu-DOTA-trastuzumab. Tracer uptake can be observed in primary breast tumor (black arrow head). The bone metastasis in the acetabulum region was visualized at day 1 and day 7 (blue arrow heads). B. SPECT/CT, CT, and SPECT images showing lymph node metastases which could not be localized on WBS (white arrow heads). Adapted from Ref [171].